MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

MDT

87.13

-1.01%↓

119.41

-0.9%↓

VEEV

167.53

+5.63%↑

HQY

83.87

+3.38%↑

NEOG

9.43

-1.77%↓

Strona główna・Stock List・Puma Biotechnology Inc

Puma Biotechnology Inc

Closed

SectorHealthcare

7.47 -1.06

Buy Sell

Overview

Share price change

24h

Current

Min

7.42

Max

7.63

Key metrics
By Trading Economics
Income	3M 12M
Sales	21M 76M
P/E Sector Avg	12.41 63.808
Profit margin	15.633
Employees	179
EBITDA	13M 27M

Recommendations
By TipRanks
Recommendations	Neutral
12 Months Forecast	-33.16% downside

Dividends
By Dow Jones
Next Earnings	7 maj 2026

Market Stats
By TradingEconomics
Market Cap	27M 385M
Previous open	8.53
Previous close	7.47

News Sentiment

By Acuity

50%

167 / 348 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

3.07 / 3.075 Support & Resistance

Puma Biotechnology Inc Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

15 kwi 2026, 23:14 UTC

Earnings

Battery Maker CATL First-Quarter Net Rose on Strong Demand

15 kwi 2026, 23:14 UTC

Earnings

Battery Maker CATL First Quarter Net Rose On Strong Demand

15 kwi 2026, 17:13 UTC

Major Market Movers

Tesla Shares Rise on Completion of AI5 Chip Design Process

15 kwi 2026, 23:39 UTC

Market Talk

Nikkei May Rise After Gains on Wall Street -- Market Talk

15 kwi 2026, 23:35 UTC

Market Talk

Major News Events

Gold Rises Amid Hopes for More U.S.-Iran Talks -- Market Talk

15 kwi 2026, 22:41 UTC

Earnings

CATL 1Q Net CNY20.74 Vs. Net CNY13.96B >300750.SZ

15 kwi 2026, 22:38 UTC

Earnings

CATL 1Q Rev CNY129.13B Vs. CNY84.70B >300750.SZ

15 kwi 2026, 22:15 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 kwi 2026, 22:15 UTC

Market Talk

J.B. Hunt Flag Fundamental Shift in 1Q -- Market Talk

15 kwi 2026, 22:14 UTC

Earnings

Lens Technology Results Weighed by Lower Rev From Smartphone, Computer Business >300433.SZ

15 kwi 2026, 22:12 UTC

Earnings

Lens Technology 1Q Oper Income CNY14.14B Vs. CNY17.06B>300433.SZ

15 kwi 2026, 22:11 UTC

Earnings

Lens Technology 1Q Loss CNY149.60M Vs. Net CNY428.88M >300433.SZ

15 kwi 2026, 22:11 UTC

Earnings

Lens Technology Swings to Loss in 1Q>300433.SZ

15 kwi 2026, 22:07 UTC

Earnings

Big Bank Earnings Show Consumers Are on Solid Ground -- Against All Odds -- Barrons.com

15 kwi 2026, 21:34 UTC

Acquisitions, Mergers, Takeovers

Skild AI Acquires Zebra Technologies' Robotics Automation Business

15 kwi 2026, 21:29 UTC

Hot Stocks

Stocks to Watch: Bank of America, Live Nation, Snap, Hermès -- WSJ

15 kwi 2026, 20:50 UTC

Market Talk

Earnings

Financial Services Roundup: Market Talk

15 kwi 2026, 20:30 UTC

Earnings

PepsiCo Cuts Prices, Revamps Products. Earnings Will Show if It's Working. -- Barrons.com

15 kwi 2026, 20:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

15 kwi 2026, 20:06 UTC

Market Talk

Silver Inches Up as Attention Turns to World Deficit -- Market Talk

15 kwi 2026, 19:46 UTC

Earnings

Acquisitions, Mergers, Takeovers

Jamie Dimon Says JPMorgan Stock Isn't Cheap. Why the Bank Is Still Buying Back Billions. -- Barrons.com

15 kwi 2026, 19:25 UTC

Market Talk

Automakers' 1Q Earnings Could Give Clues to EV Comeback -- Market Talk

15 kwi 2026, 19:00 UTC

Market Talk

U.S. Natural Gas Edges Up Ahead of Storage Data -- Market Talk

15 kwi 2026, 18:58 UTC

Market Talk

Major News Events

Oil Settles Flat As Market Awaits Conflict Developments -- Market Talk

15 kwi 2026, 18:11 UTC

Acquisitions, Mergers, Takeovers

Three Lessons From Amazon's Blockbuster Deal to Buy Globalstar -- Barrons.com

15 kwi 2026, 17:45 UTC

Acquisitions, Mergers, Takeovers

Apple CEO Tim Cook Buys Nike Stock. His Last Purchase Didn't Go So Well. -- Barrons.com

15 kwi 2026, 16:58 UTC

Earnings

Bank of America's Wealth Management Profits Rise Amid 'Resilient' U.S. Economy -- Barrons.com

15 kwi 2026, 16:52 UTC

Earnings

Snap and Other Companies Blame AI for Layoffs. Is It Just a Convenient Excuse? -- Barrons.com

15 kwi 2026, 16:46 UTC

Market Talk

Major News Events

U.S. Crude Oil Stocks Finally See Drawdowns -- Market Talk

15 kwi 2026, 16:37 UTC

Market Talk

Earnings

Global Equities Roundup: Market Talk

Peer Comparison

Price change

Puma Biotechnology Inc Forecast

Price Target

By TipRanks

-33.16% downside

12 Months Forecast

Average 5 USD -33.16%

High 5 USD

Low 5 USD

Based on 1 Wall Street analysts offering 12 month price targets forPuma Biotechnology Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Neutral

1 ratings

Buy

Hold

Sell

Based on 1 analysts giving stock ratings to Puma Biotechnology Inc - Dist in the past 3 months.

Technical Score

By Trading Central

3.07 / 3.075Support & Resistance

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

167 / 348 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Puma Biotechnology Inc

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. It also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. The company sells its products through specialty pharmacy and distributor networks. It has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds; and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of alisertib, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.